Early diagnosis and treatment of osteoarthritis can mean less pain for your patients. When choosing a treatment, remember that SYNVISC® is the only 3-injection viscosupplement that can provide patients up to 6 months of pain relief and increased mobility. SYNVISC® may be appropriate treatment if the patient is:
- No longer getting symptom relief from painkillers such as acetaminophen
- Unable to take aspirin or nonsteroidal anti-inflammatory drugs
- Taking a prescription drug for osteoarthritis of the knee but is still experiencing symptoms
- Taking multiple medications for conditions other than osteoarthritis
SYNVISC® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen.
The most commonly reported adverse events are transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely. SYNVISC® is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC® in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC® in children and in pregnant or lactating women has not been established. It is unknown whether SYNVISC® is excreted in human milk.
MEDS 4 LESS Canadian Pharmacy